Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

TARA

+ Watchlist+ Portfolio

Protara Therapeutics, Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$2.32
52-Week Range
$2.09 – $7.82
Market Cap
$144.07M
P/E (TTM)
—
EPS (TTM)
-1.39
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.99
PEG Ratio
—
Return on Equity
-57.40%
Return on Assets
-35.35%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
9.01
Debt/Equity
0.02
Total Debt
$2.44M
Free Cash Flow
$-43.87M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$19.46M

Market Snapshot

About

Protara Therapeutics is a clinical-stage biopharmaceutical company developing transformative therapies for people with cancer and rare diseases. The company focuses on IV Choline Chloride for intestinal failure associated liver disease and TARA-002 for lymphatic malformations. Protara is advancing precision medicine approaches for underserved patient populations.